Key result
Laparoscopic adjustable gastric banding reduced long-term mortality compared to medical treatment in morbidly obese patients with and without diabetes.
Why the study?
Does laparoscopic adjustable gastric banding reduce long-term mortality and incidence of cardiovascular diseases and type 2 diabetes in morbidly obese patients compared to medical treatment?
Cohort (n=1,066)
Yes
Does laparoscopic adjustable gastric banding reduce long-term mortality and incidence of cardiovascular diseases and type 2 diabetes in morbidly obese patients compared to medical treatment?
Answers are grounded in this paper and cite their sources.
Laparoscopic adjustable gastric banding is associated with significantly reduced long-term mortality and lower incidence of cardiovascular diseases and diabetes in morbidly obese patients compared to medical therapy.
BACKGROUND AND AIM: Aim of this retrospective study was to compare long-term mortality and incidence of new diseases [diabetes and cardiovascular (CV) disease] in morbidly obese diabetic and nondiabetic patients, undergoing gastric banding (LAGB) in comparison to medical treatment. PATIENTS AND METHODS: Medical records of obese patients [body mass index (BMI) > 35 kg/m(2) undergoing LAGB (n = 385; 52 with diabetes) or medical treatment (controls, n = 681; 127 with diabetes), during the period 1995-2001 (visit 1)] were collected. Patients were matched for age, sex, BMI, and blood pressure. Identification codes of patients were entered in the Italian National Health System Lumbardy database, that contains life status, causes of death, as well as exemptions, drug prescriptions, and hospital admissions (proxies of diseases) from visit 1 to September 2012. Survival was compared across LAGB patients and matched controls using Kaplan-Meier plots adjusted Cox regression analyses. RESULTS: Observation period was 13.9 ± 1.87 (mean ± SD). Mortality rate was 2.6, 6.6, and 10.1 % in controls at 5, 10, and 15 years, respectively; mortality rate was 0.8, 2.5, and 3.1 % in LAGB patients at 5, 10, and 15 years, respectively. Compared to controls, surgery was associated with reduced mortality [HR 0.35, 95 % CI 0.19-0.65, p < 0.001 at univariate analysis, HR 0.41, 95 % CI 0.21-0.76, p < 0.005 at adjusted analysis], similar in diabetic [HR 0.34, 95 % CI 0.13-0.87, p = 0.025] and nondiabetic [HR 0.42, 95 % CI 0.19-0.97, p = 0.041] patients. Surgery was also associated with lower incidence of diabetes (15 vs 48 cases, p = 0.035) and CV diseases (52 vs 124 cases, p = 0.048), and of hospital admissions (88 vs 197, p = 0.04). CONCLUSION: Up to 17 years, gastric banding is associated with reduced mortality in diabetic and nondiabetic patients, and with reduced incidence of diabetes and cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Pontiroli et al. (2016) conducted a cohort in Morbid obesity (n=1,066). Laparoscopic adjustable gastric banding vs. Medical treatment was evaluated on Long-term mortality (HR 0.41, 95% CI 0.21-0.76, p=<0.005). Laparoscopic adjustable gastric banding reduced long-term mortality compared to medical treatment in morbidly obese patients with and without diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: